Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemis: Lenvatinib + Pembrolizumab + Chemo for Thymic Carcinoma
NCT05832827Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in thymic carcinoma (TC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Sep 2023; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT05832827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832827.